Previous close | 15.60 |
Open | 15.60 |
Bid | 15.60 x 0 |
Ask | 15.90 x 0 |
Day's range | 15.60 - 15.60 |
52-week range | 12.10 - 18.10 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rika Plasma Donation System™ with the iNomi™ Nomogram. This innovation means that plasma collection volume can be determined by an individual donor's height, weight and hematocrit level on the day they donate plasma.
Terumo (TRUMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TRUMY, CIFR and STR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 28, 2023.